NO982131L - Modifisert biologisk materiale - Google Patents

Modifisert biologisk materiale

Info

Publication number
NO982131L
NO982131L NO982131A NO982131A NO982131L NO 982131 L NO982131 L NO 982131L NO 982131 A NO982131 A NO 982131A NO 982131 A NO982131 A NO 982131A NO 982131 L NO982131 L NO 982131L
Authority
NO
Norway
Prior art keywords
species
biological material
rejection
modified biological
modified
Prior art date
Application number
NO982131A
Other languages
English (en)
Other versions
NO982131D0 (no
Inventor
David James Graham White
Alan Frederick Williams
Original Assignee
Imutran Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26296038&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO982131(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB898922987A external-priority patent/GB8922987D0/en
Priority claimed from GB909017198A external-priority patent/GB9017198D0/en
Publication of NO982131L publication Critical patent/NO982131L/no
Application filed by Imutran Ltd filed Critical Imutran Ltd
Publication of NO982131D0 publication Critical patent/NO982131D0/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/108—Swine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/02—Animal zootechnically ameliorated
    • A01K2267/025—Animal producing cells or organs for transplantation
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Environmental Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Transplantation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)

Abstract

Vanligvis kan dyrevev fra én art bare transplanteres i en annen art når artene er konkordante; ellers inntrer nyperimmunawisning. Ved denne oppfin-nelse er donorvev modifisert, f.eks. ved å være transgent, for å uttrykke eller på annen måte være forbundet med ett eller flere stoffer, henvist til som homologe komplementrestriksjonsfak-torer (HCRF-er), som er aktive hos mot-takerarten når det gjelder å forhindre den fullstendige aktivering av komple-ment og derfor avvisning. Oppfinnelsen er delvis basert på den oppdagelse at den alternative vei for komplementak-tivering, og ikke den klassiske vei, er ansvarlig for hyperakutt, diskordant xenotransplantatawisning.
NO982131A 1989-10-12 1998-05-11 Modifisert biologisk materiale NO982131D0 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB898922987A GB8922987D0 (en) 1989-10-12 1989-10-12 Modified biological material
GB909017198A GB9017198D0 (en) 1990-08-06 1990-08-06 Modified biological material
PCT/GB1990/001575 WO1991005855A1 (en) 1989-10-12 1990-10-12 Modified biological material

Publications (2)

Publication Number Publication Date
NO982131L true NO982131L (no) 1992-04-10
NO982131D0 NO982131D0 (no) 1998-05-11

Family

ID=26296038

Family Applications (2)

Application Number Title Priority Date Filing Date
NO921438A NO303502B1 (no) 1989-10-12 1992-04-10 Transplanterbar dyrecelle eller transplanterbart dyrevev fra en donorart, samt anvendelse derav
NO982131A NO982131D0 (no) 1989-10-12 1998-05-11 Modifisert biologisk materiale

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO921438A NO303502B1 (no) 1989-10-12 1992-04-10 Transplanterbar dyrecelle eller transplanterbart dyrevev fra en donorart, samt anvendelse derav

Country Status (27)

Country Link
US (1) US6495735B1 (no)
EP (2) EP0495852B1 (no)
JP (1) JP3302358B2 (no)
KR (2) KR920702410A (no)
CN (2) CN1122719C (no)
AT (1) ATE139562T1 (no)
AU (1) AU654116B2 (no)
BG (1) BG61080B1 (no)
CA (1) CA2067235A1 (no)
CY (1) CY1996A (no)
DE (2) DE69027535T2 (no)
DK (1) DK0495852T3 (no)
ES (1) ES2060561T3 (no)
FI (1) FI921618A7 (no)
GR (2) GR940300004T1 (no)
HK (1) HK48497A (no)
HU (1) HUT64584A (no)
IE (1) IE75345B1 (no)
IL (2) IL95970A0 (no)
IN (1) IN171948B (no)
MY (1) MY107433A (no)
NO (2) NO303502B1 (no)
NZ (2) NZ248153A (no)
PT (2) PT95580B (no)
RO (1) RO109863B1 (no)
SG (1) SG72614A1 (no)
WO (1) WO1991005855A1 (no)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5705732A (en) * 1989-06-12 1998-01-06 Oklahoma Medical Research Foundation Universal donor cells
JP2750220B2 (ja) * 1989-07-21 1998-05-13 ワシントン ユニバーシティ 組換え産生したヒト細胞膜補助因子タンパク（ｍｃｐ）
US5846715A (en) * 1990-05-11 1998-12-08 The Austin Research Institute CD46 variants
EP0537171B1 (en) * 1990-05-11 2002-09-18 The Austin Research Institute CD46 isoforms
DE69233010T2 (de) * 1991-07-15 2004-02-19 Oklahoma Medical Research Foundation, Oklahoma Universale spenderzellen
US6916654B1 (en) * 1992-06-29 2005-07-12 Oklahoma Medical Research Foundation Universal donor cells
JPH08501451A (ja) * 1992-09-22 1996-02-20 ディーエヌエックス バイオセラピューティックス、インコーポレーテッド 異種移植臓器移植片の事前適応化、その他を目的とする膜間転移によるタンパク質の供給法
US5627264A (en) * 1994-03-03 1997-05-06 Alexion Pharmaceuticals, Inc. Chimeric complement inhibitor proteins
WO1996006165A1 (en) * 1994-08-19 1996-02-29 The General Hospital Corporation Genetically engineered swine cells
CA2227584A1 (en) 1995-08-04 1997-02-20 The General Hospital Corporation Transgenic swine and swine cells having human hla genes
US6166288A (en) * 1995-09-27 2000-12-26 Nextran Inc. Method of producing transgenic animals for xenotransplantation expressing both an enzyme masking or reducing the level of the gal epitope and a complement inhibitor
AU1933897A (en) * 1996-03-22 1997-10-17 Imutran Limited Surfaces which prevent or reduce complement activation
DE69833545T2 (de) 1997-03-26 2006-12-14 Imperial College Innovations Ltd. In der zellmembran verankertes antikoagulant-fusionsprotein
ATE313256T1 (de) 1997-07-14 2006-01-15 Nippon Meat Packers Transgene schweine
WO1999022759A1 (en) * 1997-10-31 1999-05-14 Walter Reed Army Institute Of Research Method of inhibiting side effects of pharmaceutical compositions containing amphiphilic vehicles or drug carrier molecules
SE523817C2 (sv) 1999-02-05 2004-05-18 Corline Systems Ab Användning av ett koagulationsförebyggande ämne i samband med transplantation av insulinproducerande celler
GB9905503D0 (en) 1999-03-10 1999-05-05 Adprotech Plc Novel compound formulations and methods of delivery
CA2533259C (en) * 2003-07-21 2014-01-28 Lifecell Corporation Acellular tissue matrices made from galactose .alpha.-1,3-galactose-deficient tissue
EP2464219B1 (en) 2009-08-14 2019-10-23 Revivicor, Inc. Multi-transgenic pigs for diabetes treatment
US9420770B2 (en) 2009-12-01 2016-08-23 Indiana University Research & Technology Corporation Methods of modulating thrombocytopenia and modified transgenic pigs
WO2012031273A2 (en) 2010-09-03 2012-03-08 Stem Centrx, Inc. Novel modulators and methods of use
CA2827348C (en) 2011-02-14 2021-02-23 Revivicor, Inc. Genetically modified pigs for xenotransplantation of vascularized xenografts and derivatives thereof
ES2846758T3 (es) 2013-11-04 2021-07-29 Lifecell Corp Métodos para eliminar la alfa-galactosa
CN114686427B (zh) * 2022-05-23 2022-07-29 中国人民解放军总医院第一医学中心 一种脾脏调节型b淋巴细胞及其制备方法与应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1982004443A1 (en) * 1981-06-12 1982-12-23 Ohio Univ Genetic transformation of zygotes
US4431636A (en) 1982-05-24 1984-02-14 American Cyanamid Company Bis(4-O-polyhexaose-thio)-phenyl ureas and method of use
US5109113A (en) * 1986-05-02 1992-04-28 Genentech, Inc. Membrane anchor fusion polypeptides
JPS62104594A (ja) * 1985-10-31 1987-05-15 Terumo Corp クエン酸塩利用能検査用培地組成物
JPH0742235B2 (ja) * 1985-11-08 1995-05-10 三共株式会社 自己免疫性疾病の予防・治療剤
IL82390A0 (en) * 1986-05-02 1987-10-30 Genentech Inc Nucleic acid and methods for the synthesis of novel daf compositions
GB8615942D0 (en) * 1986-06-30 1986-08-06 Animal & Food Research Council Peptide production
IL89790A (en) * 1988-04-01 2002-05-23 Johns Hopking University Nucleic acid sequences that encode and cells that produce cr1 protein and methods of production and purification
DE3830271A1 (de) 1988-09-06 1990-03-15 Goetze Otto Mittel mit immunsuppressiver wirkung
US5573940A (en) * 1989-06-12 1996-11-12 Oklahoma Medical Research Foundation Cells expressing high levels of CD59

Also Published As

Publication number Publication date
JPH05503074A (ja) 1993-05-27
DE495852T1 (de) 1994-03-31
PT95580B (pt) 1999-05-31
CN1491624A (zh) 2004-04-28
HUT64584A (en) 1994-01-28
HK48497A (en) 1997-04-25
DE69027535T2 (de) 1996-11-28
IE903649A1 (en) 1991-04-24
SG72614A1 (en) 2000-05-23
KR920702410A (ko) 1992-09-04
ES2060561T3 (es) 1996-08-01
IE75345B1 (en) 1997-08-27
EP0709459A3 (en) 1999-01-07
EP0495852B1 (en) 1996-06-19
HU9201240D0 (en) 1992-06-29
IL95970A0 (en) 1992-05-25
JP3302358B2 (ja) 2002-07-15
FI921618L (fi) 1992-04-10
US6495735B1 (en) 2002-12-17
EP0495852A1 (en) 1992-07-29
MY107433A (en) 1995-12-30
NO921438L (no) 1992-04-10
BG96329A (bg) 1993-12-24
EP0709459A2 (en) 1996-05-01
CN1122719C (zh) 2003-10-01
NO303502B1 (no) 1998-07-20
ATE139562T1 (de) 1996-07-15
PT101896B (pt) 2003-01-31
CN1051199A (zh) 1991-05-08
IL120795A0 (en) 1997-09-30
GR940300004T1 (en) 1994-02-28
DE69027535D1 (de) 1996-07-25
FI921618A0 (fi) 1992-04-10
FI921618A7 (fi) 1992-04-10
WO1991005855A1 (en) 1991-05-02
BG61080B1 (bg) 1996-10-31
DK0495852T3 (da) 1996-07-15
NO921438D0 (no) 1992-04-10
AU6539290A (en) 1991-05-16
AU654116B2 (en) 1994-10-27
KR100317106B1 (ko) 2001-12-22
NO982131D0 (no) 1998-05-11
NZ248153A (en) 1997-07-27
PT95580A (pt) 1991-09-13
RO109863B1 (ro) 1995-06-30
GR3020741T3 (en) 1996-11-30
PT101896A (pt) 1998-02-27
CY1996A (en) 1997-09-05
CA2067235A1 (en) 1991-04-13
ES2060561T1 (es) 1994-12-01
IN171948B (no) 1993-02-13
NZ235657A (en) 1994-05-26

Similar Documents

Publication Publication Date Title
EP0709459A3 (en) Modified biological material
MD970009A (en) Methods for inducing T cells tolerance to donor tissues or organs
WO1997012035A3 (en) Transgenic animals for xenotransplantation with reduced antibody-mediated rejection
Merola et al. Progenitor-derived human endothelial cells evade alloimmunity by CRISPR/Cas9-mediated complete ablation of MHC expression
AU9058091A (en) Preparation of nucleic acid samples
AU667530B2 (en) Removal of antibodies from blood-derived compositions while retaining coagulation factors
AR018489A1 (es) Uso de una celula realizada geneticamente que comprende dna que codifica una proteina de gen de activacion de linfocito 3 (lag-3) transmembrana y de dicha proteina para la fabricacion de un medicamento util para inducir la proteccion del rechazo de injerto y uso de moleculas antisentido de las misma
Groth The potential advantages of transplanting organs from pig to man: A transplant Surgeon's view
ATE310828T1 (de) Implantat und vektor zur behandlung von erworbenen krankheiten
NL7902024A (nl) Werkwijze voor het verbeteren van de werking van semipermeabele membranen, alsmede het op deze wijze behandelde semipermeabele membraan.
Berrian et al. Transplantation immunity involving the H-3 locus: graft survival times
WO1999053042A3 (en) Biological material with increased expression of endogenous complement regulatory molecules
DK76688A (da) Vaccine indeholdende f-proteinet fra aids-virus
Coffaro TRANSPLANTATION IMMUNITY IN THE SEA URCHIN.
Turillazzi Distinguishing features of the social behaviour of Stenogastrinae wasps.
Uddin et al. Localization of kallikrein in the guinea-pig submandibular gland
DeVore et al. HEPATITIS B CORE ANTIBODY POSITIVE DONORS ARE A USEFUL SOURCE OF ALLOGRAFTS FOR LIVER TRANSPLANTATION.: 234
AU2020397953A8 (en) Placenta-derived allogeneic CAR-T cells and uses thereof
林政行 et al. Life history and larval food plants of Notodontidae in southern Taiwan
Martin et al. DOES TRANSPLANTED MELD SCORE MAKE A DIFFERENCE IN POST TRANSPLANT QUALITY OF LIFE?: 235
Martin et al. REDUCING FRACTURE INCIDENCE IN LIVER TRANSPLANT RECIPIENTS WITH AGGRESSIVE PROPHYLAXIS.: 233
DE69631528D1 (de) Serumzusammensetzungen zur hemmung von retroviren und tumorwachstum
CA2254889A1 (en) A promoter gene for a porcine complement inhibitor